GlaxoSmithKline (GSK) and Theravance, Inc. THRX today announced that the licence application for the use of fluticasone furoate (FF) and vilanterol (VI) (proposed brand name RELVAR™ ELLIPTA™) in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results